Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia

7 listopada 2013 zaktualizowane przez: GlaxoSmithKline

A Phase IIa, Randomized, Single-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of 28-day Repeat Oral Doses of GSK1278863A in Anemic Pre-dialysis and Hemodialysis-dependent Patients

The purpose of this study is to characterize the safety and efficacy of repeat doses of compound 1278863A in subjects with anemia.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

Compound 1278863A is a novel small molecule agent, which stimulates erythropoiesis through inhibition of hypoxia-inducible factor (HIF)-prolyl hydroxylases (EGLNs). This compound is being developed for the treatment of anemia. This study, PHI112844, will be the first administration of compound 1278863A to investigate the pharmacodynamics/efficacy, safety, tolerability, and pharmacokinetics of repeat oral doses in anemic pre-dialysis patients with moderate or severe renal impairment and in hemodialysis-dependent patients.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

107

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Australia
    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
        • GSK Investigational Site
      • Gosford, New South Wales, Australia, 2250
        • GSK Investigational Site
      • St. Leonards, New South Wales, Australia, 2065
        • GSK Investigational Site
    • Queensland
      • Herston, Queensland, Australia, 4029
        • GSK Investigational Site
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • GSK Investigational Site
      • Reservoir, Victoria, Australia, 3073
        • GSK Investigational Site
  • Federacja Rosyjska
      • Ekaterinburg, Federacja Rosyjska, 620102
        • GSK Investigational Site
      • Moscow, Federacja Rosyjska, 125101
        • GSK Investigational Site
      • Moscow, Federacja Rosyjska, 119620
        • GSK Investigational Site
      • Moscow, Federacja Rosyjska, 109240
        • GSK Investigational Site
      • Moscow, Federacja Rosyjska, 115093
        • GSK Investigational Site
      • Moscow, Federacja Rosyjska, 119021
        • GSK Investigational Site
      • Moscow, Federacja Rosyjska, 109472
        • GSK Investigational Site
      • Moscow, Federacja Rosyjska, 123183
        • GSK Investigational Site
      • Nizhny Novgorod, Federacja Rosyjska, 603032
        • GSK Investigational Site
      • Perm, Federacja Rosyjska, 614097
        • GSK Investigational Site
      • Saratov, Federacja Rosyjska, 410053
        • GSK Investigational Site
      • Smolensk, Federacja Rosyjska, 214006
        • GSK Investigational Site
      • St-Petersburg, Federacja Rosyjska, 197110
        • GSK Investigational Site
      • St. Petersburg, Federacja Rosyjska, 196247
        • GSK Investigational Site
      • St. Petersburg, Federacja Rosyjska, 197022
        • GSK Investigational Site
      • St. Petersburg, Federacja Rosyjska, 191104
        • GSK Investigational Site
      • St. Petersburg, Federacja Rosyjska, 191015
        • GSK Investigational Site
      • St. Petersburg, Federacja Rosyjska, 191186
        • GSK Investigational Site
      • St. Petersburg, Federacja Rosyjska, 195067
        • GSK Investigational Site
      • Volzhsky, Federacja Rosyjska, 404120
        • GSK Investigational Site
      • Yaroslavl, Federacja Rosyjska, 150062
        • GSK Investigational Site
  • Indie
      • Bangalore, Indie, 560017
        • GSK Investigational Site
      • Bangalore, Indie, 560004
        • GSK Investigational Site
      • Hyderabad, Indie, 500012
        • GSK Investigational Site
      • Hyderabad, Indie, 5000068
        • GSK Investigational Site
      • Kalapet Pondicherry, Indie, 605014
        • GSK Investigational Site
      • Mumbai, Indie, 400008
        • GSK Investigational Site
      • New Delhi, Indie
        • GSK Investigational Site
      • Vishakha Patnam, Indie, 530002
        • GSK Investigational Site
  • Nowa Zelandia
      • Auckland, Nowa Zelandia, 1150
        • GSK Investigational Site
      • Christchurch, Nowa Zelandia, 8140
        • GSK Investigational Site

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 85 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Male or female between 18 and 85 years of age inclusive, at the time of signing the informed consent.

  2. A male or female is eligible to enroll and participate in this study if he/she:

    1. (Part 1) has Moderate to Severe Renal Impairment (equivalent to NKF KDOQI Stage 3 or 4, not receiving dialysis) as determined by estimated Glomerular Filtration Rate (eGFR) calculated by the abbreviated MDRD equation, and not expected to go on dialysis until ≥ 8 weeks after first administration of investigational product. Stage 5, non-dialysis patients with eGFR of 10 15 mL/min per 1.73 m2 will also be eligible for Part 1 on a case-by-case basis.
    2. (Part 2) has Severe Renal Impairment and has been on stable hemodialysis treatment for 1 month prior to Screening (subjects with planned transition to hemodialysis) or 3 months prior to Screening (subjects emergently placed on hemodialysis). These subjects are equivalent to NKF KDOQI Stage 5.
    3. otherwise healthy or considered clinically stable with respect to underlying renal impairment and with respect to underlying/chronic disease as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
    4. has clinical laboratory test results that are considered clinically stable in the opinion of the principal investigator, especially if the clinical abnormality or laboratory parameter is deemed associated with the patient's underlying renal impairment.

  3. Meets the following erythropoiesis stimulating agent (ESA) criteria:

    1. The patient is ESA naïve OR
    2. If the patient has a scheduled ESA interval which is ≤ 7 days, ESA treatment must be discontinued for at least 7 days OR
    3. If the patient has a scheduled ESA interval which is > 7 days, ESA treatment must be discontinued for at least that scheduled interval length (eg discontinued ≥ 14 days for a scheduled 14 day ESA interval) AND The patient will not resume ESA treatment until completion of the Follow-up Visit (Day 57).

  4. Has a hemoglobin value:

    1. For ESA naïve patients: ≤11.0 g/dL
    2. For patients receiving ongoing ESA treatment: ≤11.5 g/dL at Screening with a re check value of ≤11.0 g/dL after appropriate ESA discontinuation according to Inclusion 3 and prior to commencing study drug dosing.

  5. 5. Has serum ferritin at Screening:

    1. ≥40 μg/L with the absence of microcytic or hypochromic RBCs (regardless of transferrin saturation %) OR
    2. 25-39 μg/L with transferrin saturation % ≥20% (fraction saturation ≥0.20) and the absence of microcytic or hypochromic RBCs
  6. Has Vitamin B12 and folate above the lower limit of normal at Screening

  7. A female patient is eligible to participate if she is:

    1. of childbearing potential, and must agree to use one of the contraception methods in Section 8.1.1. This criterion must be followed from the time of Screening until completion of the Follow-up Visit (Day 57) OR
    2. of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<140 pmol/L) is confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods in Section 8.1.1 if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.
  8. Male patients must agree to use one of the contraception methods listed in Section 8.1.2. This criterion must be followed from the time of the first dose of study drug until completion of the Follow-up Visit (Day 57).
  9. Body weight ≥ 45 kg
  10. QTcB or QTcF < 450 msec; or QTc < 480 msec in patients with bundle branch block. These should be based on an average of triplicate values obtained at Screening.
  11. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria:

  1. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months prior to Screening and one of the following:

    • evidence of autoimmune anemia
    • prior anti-viral therapy
    • evidence of liver damage
  2. A positive test for HIV antibody.
  3. A pre-study drug screen that is positive due to drug use not associated with a current medication prescription. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
  4. A value at Screening is greater than 1.5 times the upper limit of reference range for AST, ALT, or direct bilirubin.
  5. Hemolysis/hemolytic anemia or active bleeding/blood loss
  6. Androgen therapy within 8 weeks prior to first dose of study drug (Day 1).
  7. Red blood cell transfusion within 90 days prior to first dose of study drug (Day 1).

  8. 8. Iron replacement therapy:

    1. Intravenous iron replacement therapy within 30 days prior to the first dose of study drug on Day 1 until completion of the Follow-up Visit (Day 57).
    2. Oral iron replacement therapy started or discontinued within 30 days prior to Screening. (Patients currently receiving oral iron replacement therapy which was initiated at least 30 days prior to Screening, will be allowed to continue their oral iron replacement therapy during the study and should not discontinue the therapy until after completion of all study drug doses and Day 29 assessments.)
  9. History of thrombosis defined as deep vein thrombosis, stroke, pulmonary embolism or other thrombosis related condition within 1 year prior to Screening.
  10. Known active decompensated hyperparathyroidism or history of bone marrow fibrosis.
  11. Systemic hematologic disease, including, but not limited to sickle cell disease, hemosiderosis, hemochromatosis, myelodysplastic syndrome, hematologic malignancy, myeloma
  12. Post-renal transplantation patients with functioning transplant. (Failed transplant subjects back on hemodialysis are eligible).
  13. Acute peptic ulcer disease or history of chronic rectal bleeding.
  14. History of malignancy tumor within 5 years prior to Screening or are receiving medication for cancer. Non-melanoma skin cancer within the past 5 years that has been definitively removed is allowed.
  15. Patients with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, and/or hepatic function that could interfere with the absorption, metabolism, and/or excretion of the study drugs. Examples of conditions that could interfere with normal gastrointestinal anatomy or motility include gastrointestinal bypass surgery, partial or total gastrectomy, small bowel resection, vagotomy, malabsorption, Crohn's disease, ulcerative colitis, or celiac sprue. Examples of conditions that could interfere with hepatic function include Gilberts syndrome.
  16. Active infection or acute inflammatory disease as determined by clinical assessment.
  17. Class III heart failure with evidence of recent progression (worsening dyspnea, hospitalization within 2-3 months for symptoms, etc), or Class IV heart failure, as defined by the New York Heart Association (NYHA) functional classification system.
  18. Uncontrolled hypertension (diastolic BP >100 mmHg or systolic BP >160 mmHg at Screening)
  19. Myocardial infarction or acute coronary syndrome within 1 year prior to Screening.
  20. History of seizure disorder.
  21. Proliferative choroidal or retinal disease, such as neovascular age-related macular degeneration or proliferative diabetic retinopathy that is likely to require treatment (intraocular injections or laser photocoagulation) during the study.
  22. Pregnant females as determined by positive serum or urine hCG test at Screening or prior to the first dose of study drug (Day 1).
  23. Lactating females.
  24. History of drug abuse or dependence within 6 months prior to Screening.
  25. Unwillingness or inability to follow the procedures, or lifestyle and/or dietary restrictions outlined in the protocol.

  26. Use of prescription drugs within 7 days prior to first dose of study drug (Day 1) until after completion of all study drug doses and Day 29 assessments:

    • which are know to be inhibitors of CYP 2C8 OR
    • which are known to be both CYP 2C8 and OATP1B1 substrates OR
    • which rely mainly on OATP1B1/1B3 for hepatic clearance as described in Section 9 of the protocol.
  27. Use of prescription drugs within 14 days prior to first dose of study drug (Day 1) until completion of all study drug doses and Day 29 assessments, which are known to be inducers of CYP 2C8, as described in Section 9 of the protocol.
  28. Use of non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study drug (Day 1) through the Follow-up Visit (Day 57), unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise patient safety and GSK Medical Monitor concurs.
  29. History of sensitivity to any of the study drugs, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  30. History of sensitivity to heparin or heparin-induced thrombocytopenia. (if the clinical site uses heparin to maintain intravenous cannula patency)
  31. The patient has participated in a clinical trial and has received an experimental investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  32. Exposure to more than four experimental investigational products within 12 months prior to the first dose of study drug (Day 1).
  33. Patient is mentally or legally incapacitated.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Pojedynczy

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Komparator placebo: Grupa 2
Placebo
Lek: Placebo
pasujące placebo
Eksperymentalny: Group 1
Active Drug
Lek: 1278863A
25mg, 50mg, 100mg

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Ramy czasowe
Zgłaszanie zdarzeń niepożądanych
Ramy czasowe: przez cały okres studiów
przez cały okres studiów
Rate of response for increase from baseline of hemoglobin levels
Ramy czasowe: Pre-dose, Day 1, Day 15, Day 22, Follow-up
Pre-dose, Day 1, Day 15, Day 22, Follow-up
Safety Labs (Chemistry)
Ramy czasowe: Screening, Day 1, 4, 8, 15, 22, 29, 36, 57
Screening, Day 1, 4, 8, 15, 22, 29, 36, 57
Safety Labs (Hematology)
Ramy czasowe: Screening, Day 1, 4, 8, 15, 22, 29, 36, 57
Screening, Day 1, 4, 8, 15, 22, 29, 36, 57
Safety Labs (Urinalysis)
Ramy czasowe: Screening, Day 1, 4, 8, 15, 22, 29, 36, 57
Screening, Day 1, 4, 8, 15, 22, 29, 36, 57
Vital Signs (blood pressure and heart rate)
Ramy czasowe: Screening, Day 1, 4, 8, 15, 22, 29, 36, 57
Screening, Day 1, 4, 8, 15, 22, 29, 36, 57
ECG
Ramy czasowe: Screening, Day 1, 4, 8, 15, 22, 29, 36, 57
Screening, Day 1, 4, 8, 15, 22, 29, 36, 57

Miary wyników drugorzędnych

Miara wyniku
Ramy czasowe
AUC (0-∞), Cmax, tmax, t½
Ramy czasowe: Day 1, 15, 22
Day 1, 15, 22
Actual values and change from baseline for erythropoietin, absolute and percent reticulocytes, hematocrit, and total RBCs
Ramy czasowe: Day 1, 15, 22, Folllow-up
Day 1, 15, 22, Folllow-up
Actual values and change from baseline for VEGF, hepcidin, TIBC
Ramy czasowe: Day 1, 15, 22, Follow-up
Day 1, 15, 22, Follow-up
Actual values and change from baseline for transferrin saturation, serum iron, serum ferritin
Ramy czasowe: Screening, Day 1, 15, 29, 57
Screening, Day 1, 15, 29, 57
Actual value and change from baseline for fetal hemoglobin
Ramy czasowe: Day 1, 29, 57
Day 1, 29, 57

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

GlaxoSmithKline

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 marca 2010

Zakończenie podstawowe (Rzeczywisty)

1 lutego 2011

Ukończenie studiów (Rzeczywisty)

1 lutego 2011

Daty rejestracji na studia

Pierwszy przesłany

11 stycznia 2010

Pierwszy przesłany, który spełnia kryteria kontroli jakości

11 stycznia 2010

Pierwszy wysłany (Oszacować)

12 stycznia 2010

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Oszacować)

11 listopada 2013

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

7 listopada 2013

Ostatnia weryfikacja

1 lipca 2013

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • 112844
  • PHI112844 (Inny identyfikator: Octagon Research)

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Choroba nerek

Badania kliniczne na Placebo

Wyszukaj podobne próby

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

CROs by country

CROs in South Africa

Warunki

Rzadkie choroby

Interwencje lekowe

Suplementy diety

Sponsor / Współpracownicy

Lokalizacje

Subskrybuj